Free tool
Find any stock
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
72 stocks worldwide match these filters · market cap, largest first. Clear filters
Data as of Aug 27, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | Price | vs 52-week high | 1M return |
|---|---|---|---|---|---|---|
| ABNX.PA | ABIONYX Pharma SA | Rare disease | $98.59M | 1.97 EUR | −62.68% | +5.79% |
| 0RAG.L | ABIONYX Pharma SA | Rare disease | $95.77M | 2.01 EUR | −62.00% | +3.40% |
| ILA.AX | Island Pharmaceuticals Limited | Rare disease | $95.70M | 0.45 AUD | −28.57% | +18.42% |
| FBIO | Fortress Biotech, Inc. |
Every company we cover sits in at least one of these lists. Each one opens as a full table of its members, ordered by market value.
The 11 business sectors every covered company is classified into.
The 20 narrower groupings we keep for parts of the market that do not split neatly by sector.
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock, $9.90 each. Already know the symbol?
| $94.38M |
| $2.81 |
| −37.97% |
| −17.11% |
| PLYX | Polaryx Therapeutics, Inc. | Rare disease | $94.21M | $2.09 | −95.73% | +5.03% |
| PAR.AX | Paradigm Biopharmaceuticals Limited | Rare disease | $92.46M | 0.22 AUD | −54.26% | +30.30% |
| RLYB | Rallybio Corporation | Rare disease | $89.64M | $16.88 | −3.95% | +4.49% |
| GOSS | Gossamer Bio, Inc. | Rare disease | $85.01M | $0.17 | −95.51% | −15.17% |
| RCE.AX | Recce Pharmaceuticals Ltd | Rare disease | $82.40M | 0.38 AUD | −48.63% | +2.74% |
| TELO | Telomir Pharmaceuticals, Inc. | Rare disease | $80.47M | $1.17 | −44.05% | −0.85% |
| TENX | Tenax Therapeutics, Inc. | Rare disease | $79.34M | $2.12 | −89.07% | −86.58% |
| STX.L | Shield Therapeutics plc | Rare disease | $71.97M | 4.85 GBP | −61.20% | −15.65% |
| FBIOP | Fortress Biotech, Inc. | Rare disease | $71.45M | $18.40 | −14.14% | −1.92% |
| ALTHX.PA | THX Pharma Société Anonyme | Rare disease | $71.22M | 4.18 EUR | −18.14% | +5.16% |
| SPRO | Spero Therapeutics, Inc. | Rare disease | $71.05M | $1.22 | −60.39% | +2.09% |
| RNTX | Rein Therapeutics Inc. | Rare disease | $69.01M | $0.80 | −63.30% | +2.30% |
| IMA | ImageneBio, Inc. | Rare disease | $61.64M | $5.43 | −62.13% | −5.73% |
| 0IIM.L | Esperion Therapeutics, Inc. | Rare disease | $61.56M | $3.19 | −23.51% | +0.14% |
| SCYX | SCYNEXIS, Inc. | Rare disease | $56.41M | $5.67 | −7.83% | +56.20% |
| ATYR | aTyr Pharma, Inc. | Rare disease | $54.05M | $0.55 | −91.52% | +11.54% |
| NSRX | Nasus Pharma Ltd. | Rare disease | $48.01M | $4.05 | −59.46% | +33.66% |
| MCRB | Seres Therapeutics, Inc. | Rare disease | $47.81M | $4.76 | −84.12% | −0.83% |
| EDSA | Edesa Biotech, Inc. | Rare disease | $47.63M | $4.94 | −75.69% | −0.60% |
| GRCE | Grace Therapeutics, Inc. | Rare disease | $46.28M | $2.15 | −58.49% | −4.44% |
| MREO | Mereo BioPharma Group plc | Rare disease | $44.39M | $0.28 | −88.27% | −10.03% |
| BOT.AX | Botanix Pharmaceuticals Limited | Rare disease | $41.30M | 0.02 AUD | −88.24% | +5.26% |
| NNVC | NanoViricides, Inc. | Rare disease | $32.68M | $1.28 | −42.60% | −20.50% |
| QNCX | Quince Therapeutics, Inc. | Rare disease | $31.84M | $31.31 | −31.19% | +61.64% |
| IMM.L | ImmuPharma plc | Rare disease | $31.75M | 3.41 GBP | −82.42% | −24.22% |
| 520A.T | J-PHARMACEUTICALS CO LTD | Rare disease | $31.71M | 280.00 JPY | −65.39% | +4.09% |
| ALDVI.PA | Advicenne S.A. | Rare disease | $30.93M | 1.75 EUR | −25.53% | +4.79% |
| 4591.T | Ribomic Inc. | Rare disease | $30.52M | 86.00 JPY | −28.33% | +21.13% |
| BRNS | Barinthus Biotherapeutics plc | Rare disease | $28.86M | $0.71 | −61.40% | +23.93% |
| 0RQJ.L | Saniona AB (publ) | Rare disease | $27.98M | 11.80 SEK | −58.08% | +0.47% |
| RVX.TO | Resverlogix Corp. | Rare disease | $24.81M | 0.10 CAD | −33.33% | 0.00% |
| JSPR | Jasper Therapeutics, Inc. | Rare disease | $23.96M | $0.72 | −76.46% | +13.43% |
| TVRD | Tvardi Therapeutics, Inc. | Rare disease | $23.74M | $1.78 | −95.92% | −27.05% |
| 4884.T | Kringle Pharma, Inc. | Rare disease | $22.30M | 440.00 JPY | −26.79% | +42.86% |
| COCP | Cocrystal Pharma, Inc. | Rare disease | $21.57M | $1.12 | −58.05% | +20.43% |
| VYNE | VYNE Therapeutics Inc | Rare disease | $19.07M | $28.56 | −39.17% | +3080.40% |
| KTTA | Pasithea Therapeutics Corp. | Rare disease | $19.05M | $0.57 | −72.33% | +26.67% |
| CALC | CalciMedica, Inc. | Rare disease | $18.06M | $0.59 | −91.84% | −18.18% |
| CMMB | Chemomab Therapeutics Ltd. | Rare disease | $16.85M | $2.59 | −37.14% | +81.12% |
| 4881.T | FunPep Company Limited | Rare disease | $15.92M | 51.00 JPY | −60.77% | +2.00% |
| HIND | Vyome Holdings, Inc. | Rare disease | $15.16M | $2.16 | −82.00% | +8.54% |
| ALBPS.PA | Biophytis S.A. | Rare disease | $11.98M | 0.08 EUR | −61.45% | +422.88% |
| AZTR | Azitra, Inc. | Rare disease | $10.48M | $0.17 | −87.65% | +33.00% |
| QNRX | Quoin Pharmaceuticals, Ltd. | Rare disease | $10.40M | $5.18 | −87.61% | +23.33% |
| ANNX.ST | Annexin Pharmaceuticals AB (publ) | Rare disease | $10.27M | 13.60 SEK | −54.36% | +7.09% |
| PHR.WA | Pharmena S.A. | Rare disease | $9.45M | 3.14 PLN | −27.31% | +1.62% |
| IMRN | Immuron Limited | Rare disease | $9.20M | $1.14 | −52.30% | +4.11% |
| IMC.AX | Immuron Limited | Rare disease | $8.58M | 0.04 AUD | −62.24% | +8.82% |
| SNGX | Soligenix, Inc. | Rare disease | $8.36M | $0.38 | −88.84% | +6.67% |
| XCUR | Exicure, Inc. | Rare disease | $8.25M | $1.26 | −86.71% | −27.59% |
| INM | InMed Pharmaceuticals Inc. | Rare disease | $7.64M | $1.43 | −42.80% | −14.37% |
| VBS.AX | Vectus Biosystems Limited | Rare disease | $6.65M | 0.17 AUD | −62.64% | +30.77% |
| PULM | Pulmatrix, Inc. | Rare disease | $5.57M | $1.53 | −72.26% | −9.23% |
| BIOSGN.ST | Biosergen AB (publ) | Rare disease | $5.31M | 2.48 SEK | −95.51% | +262.31% |
| CVKD | Cadrenal Therapeutics, Inc. | Rare disease | $4.80M | $1.55 | −89.41% | −22.89% |
| JAGX | Jaguar Health, Inc. | Rare disease | $4.78M | $0.92 | −98.92% | −4.63% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Size bands, from the largest companies down to the smallest we cover.
The 23 listing venues our coverage spans, across the Americas, Europe and Asia-Pacific.
5 lists built on a single stated criterion, such as paying a dividend or trading near a 52-week high.
The largest one day percentage moves in either direction, among the mid, large and mega cap companies we cover.